Detalles de la búsqueda
1.
Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
BMC Med
; 22(1): 42, 2024 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38281914
2.
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.
Cancer Immunol Immunother
; 72(9): 2949-2960, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37247023
3.
Single-cell RNA sequencing in cancer research: discovering novel biomarkers and therapeutic targets for immune checkpoint blockade.
Cancer Cell Int
; 23(1): 313, 2023 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38066642
4.
Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma.
BMC Cancer
; 23(1): 451, 2023 May 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37202783
5.
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer.
Cancer Immunol Immunother
; 71(8): 1889-1896, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022908
6.
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?
Hepatology
; 76(6): E127-E128, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35689628
7.
Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.
Hepatology
; 76(4): E84-E85, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35604038
8.
Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer.
Int Immunopharmacol
; 129: 111642, 2024 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38325044
9.
Radiation Therapy With Combination Therapy of Immune Checkpoint Inhibitors and Antiangiogenic Therapy for Hepatocellular Carcinoma.
Int J Radiat Oncol Biol Phys
; 118(5): 1461-1471, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37433375
10.
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study.
Int J Surg
; 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704621
11.
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma.
Biomark Res
; 12(1): 26, 2024 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38355603
12.
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma.
J Immunother Cancer
; 12(6)2024 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38844407
13.
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer.
Biomark Res
; 12(1): 56, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38831368
14.
Prognostic value of SAT volume and density for predicting the outcome of patients with unresectable HCC treated with lenvatinib plus anti-PD-1 antibodies.
Am J Cancer Res
; 13(3): 912-921, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37034208
15.
Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer.
Am J Cancer Res
; 13(3): 1026-1037, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37034211
16.
Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
World J Gastroenterol
; 29(10): 1614-1626, 2023 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36970591
17.
The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.
Am J Cancer Res
; 13(8): 3582-3590, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37693157
18.
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Hepatol Int
; 17(3): 709-719, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36753026
19.
Development and validation of a genomic instability-related lncRNA prognostic model for hepatocellular carcinoma.
Front Genet
; 13: 1034979, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36712850
20.
Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.
Front Cell Dev Biol
; 10: 910749, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35912098